HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.7%

Neg 0% Neu 92.7% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.